Drug Profile
CP 866087
Alternative Names: CP-866,087Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Female sexual dysfunction; Obesity
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-II for Female sexual dysfunction in Sweden (PO)
- 31 Jul 2007 Phase-II clinical trials in Female sexual dysfunction in Sweden (PO)
- 30 Jun 2007 Phase-II clinical trials in Obesity in USA (PO)